Understand the source comparison
Best Research Peptides for Telomere Length Research: Comparison
Epitalon Telomerase activation via pineal-hypothalamic signaling 0.5–10 μg/g body weight Subcutaneous or intraperitoneal injection 16–33% increase in telomerase activity over 10–20 passages (human fibroblasts, Oncotarget 2019) Transient effect. Activity return
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Epitalon
- Telomerase activation via pineal-hypothalamic signaling
- 0.5–10 μg/g body weight
- Subcutaneous or intraperitoneal injection
- 16–33% increase in telomerase activity over 10–20 passages (human fibroblasts, Oncotarget 2019)
- Transient effect. Activity returns to baseline within 72 hours post-dose; receptor desensitization after 14–21 days continuous use
- Best for pulsed protocols targeting acute telomerase upregulation in short study windows
- FOXO4-DRI
- Senescent cell clearance (indirect telomere preservation by reducing SASP-mediated oxidative damage)
- 5 mg/kg every 3–4 days
- Subcutaneous or intravenous injection
- 70% reduction in senescent cell burden; 18% slower telomere attrition rate in adjacent healthy cells (Erasmus University, Cell 2017)
- Does not directly activate telomerase. Effects depend on baseline senescent cell load; limited data in young or low-senescence models
- Best for aged models where senescent cell accumulation drives telomere shortening
- TA-65 (Cycloastragenol)
- TERT protein stabilization via Hsp90 binding; transcriptional upregulation
- 5–50 mg/kg daily (oral)
- Oral administration
- Mean 530 base pair increase in CD8+ T cell telomeres after 12 months in human RCT (Rejuvenation Research 2016)
- Tissue-specific response. Minimal effect in bone marrow stem cells; requires 8–12 weeks minimum to detect measurable change
- Best for long-duration studies requiring sustained TERT stabilization without injection protocols